HomeInfrastructureGujarat Medicine Procurement Report Flags Waste and Quality Gaps

Gujarat Medicine Procurement Report Flags Waste and Quality Gaps

A report on Gujarat’s public-health system has highlighted a gap between government medicine procurement and hospital use, alongside concerns over the quality testing of medicines supplied to the state system.

According to Sandesh, the Gujarat Medical Services Corporation Limited purchased medicines worth approximately Rs 536 crore in 2023-24, Rs 736 crore in 2024-25 and Rs 727 crore in 2025-26. The reported total is around Rs 2,000 crore over three years.

The report said Gujarat Medical Education and Research Society-affiliated hospitals had more than 100 essential medicines remaining unused in each of the three years. It cited 133 medicines in 2023-24, 141 in 2024-25 and 104 in 2025-26. The health department reportedly attributed the unused stock in Bhavnagar, in one instance, to the absence of an orthopaedic doctor despite the medicines being available.

The article also reported that drug samples had failed quality tests during a two-year period. However, the figures in the source material are inconsistent: its headline and summary refer to 280 failed samples, while the body refers to 290. The body said 163 of the samples were manufactured by companies from outside Gujarat and 127 by manufacturers based in the state.

For the 127 samples linked to Gujarat manufacturers, the report said show-cause notices were issued to the concerned firms. It stated that notices were issued to 98 manufacturers, licences of 13 manufacturers were suspended after notices, and one manufacturing permission was cancelled while the licence was suspended. It also said further legal action had been initiated against other manufacturers.

The source additionally reported that 21 health department officials and employees had been reappointed after retirement, including three officials aged above 62. It said the department records an average of 600 to 700 retirements each year.

The report’s chronology requires clarification before the figures can be treated as confirmed. It refers to data up to December 2023 while also presenting figures for 2025-26, and does not provide the underlying procurement, stock-utilisation or drug-testing documents. Verification from the Gujarat Medical Services Corporation, the state health department and relevant drug-control authorities is therefore necessary to establish the final sample count, testing period, status of regulatory action and the scale of unused stock.



RELATED ARTICLES

Most Popular

Latest News